

#4



SEQUENCE LISTING

<110> INSTITUT PASTEUR

<120> Therapeutic methods and compositions for the treatment
of impaired interpersonal and behavioral disorders

<130> BET 01/1201

<140> PCT/EP00/06259

<141> 2000-06-22

<150> US/140,563

<151> 1999-06-23

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa can be any amino acid

<400> 1

Xaa His Asn Pro Arg

1

5

<210> 2

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 2

Gln His Asn Pro Arg

1

5

<210> 3

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa can be any amino acid

<400> 3

Xaa His Asn Pro

1

<210> 4

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 4

Gln His Asn Pro

1

<210> 5

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 5

Arg Gln His Asn Pro Arg

1

5

<210> 6

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 6

Val Arg Gly Pro Arg Arg Gln His Asn Pro Arg

1

5

10

<210> 7

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 7

Gln His Asn Leu Arg
1 5

<210> 8

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 8

Arg Gln His Asn Leu Arg
1 5

<210> 9

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 9

Gly Gln His Gly Pro Arg
1 5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 10

Gly Gln His Asp Pro Thr
1 5